PureTech Health’s Vor wins FDA fast-track approval for cancer drug

Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
The US Food and Drug Administration granted the designation to VOR33, a hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukaemia.